(Reuters) -AstraZeneca on Friday topped analyst expectations for second-quarter revenue and income, helped by increased demand for its most cancers medicines.
Core earnings got here in at $1.72 cents per share for the three months ended June 30, on income of about $10.8 billion.
Analysts on common had been anticipating revenue of $1.56 cents per share on income of round $10.5 billion, Refinitiv information confirmed.
The London-listed firm additionally raised its full-year income steerage, saying it expects it to rise by a share within the low twenties fairly than the excessive teenagers forecast beforehand.
On Friday, the corporate additionally revealed the substitute for non-executive Chairman Leif Johansson – Michel Demaré will take over as soon as Johansson retires subsequent yr. Demaré at the moment serves because the chair of AstraZeneca (NASDAQ:)’s remuneration committee.
Johansson turned chairman in 2012, across the identical time Frenchman Pascal Soriot took cost as chief government.